Genzon pharmaceutical Group is a wholly owned modern Pharmaceutical enterprise which was funded and operated by Genzon Group. It integrates the R&D, producing and selling of pharmaceutical products. Genzon Phamaceuticals Group owns four subsidiaries: Shenzhen Kexing Biotech Co., Ltd., Shandong Kexing Bioproducts Co., Ltd, Shenzhen Tongan pharmaceuticals Co., Ltd. and Shenzhen Kexing pharmaceuticals Import & Export Co., Ltd.
With years of efforts, Genzon Pharmaceuticals Group has achieved its strong strength and competitive advantages in the industry. Currently, the Group’s main products include Recombinant Human Interferon α 1b for Injection (SINOGEN), Recombinant human Erythropoietin (EPOSINO), Recombinant Human Granulocyte Colony-Stimulating Factor Injection (WHITE-C), Clostridium butyricum Bifidobacterium (CHANGLEKANG); Chinese traditional patent pharmaceutical Kehuang Capsule, and etc.
Moving forward, GENZON pharmaceutical Group will make a good use of its new platform, to develop a multi-product combination with Chemical drugs, traditional Chinese medicines, and health care products. The company wish to contribute to the pharmaceutical industry and human health improvement by focusing on "Liver disease, kidney disease, cancer, and pediatrics"areas.
No.1 brand in China's interferon market, a breakthrough in China genetic revolution.
The first α1b type interferon using Chinese gene cloning and expression in the world, its clinical use is most consistent with the Chinese natural antiviral state. Due to high purity, good stability, the minimum neutralizing antibody formed, obvious curative effect, low incidence of adverse reactions, Sinogen broke the monopoly of interferon products from European and American countries in China and consolidated its status as the No.1 brand in the interferon market.
For Kexing and even for the whole China biomedical research field, Sinogen leads a whole new biotechnology revolution, marked the industry as a milestone significance.
No.1 export brand of EPO in China
As the first genetically engineered drug in China, EPOSINO is produced strictly complying with European standards. The product has been exported to more than 30 countries and regions, making it a EPO product with the largest export share in China. In October 2011, the new indications 10000IU/ml EPO was brought into the market, only three companies in China produced this indication.
In 2002, EPOSINO was awarded as China High-quality Product certificate by French Science and Technology Quality Supervision and Evaluation Committee, and was recognized as recommended products in EU market by China Council for the Promotion of International Trade and the French Science and Technology Quality Supervision and Evaluation Committee.
European Pharmacopoeia quality standards, genetically engineered drugs with clinical verification for nearly 20 years
With advanced American technology and GMP standard, recombinant Human Granulocyte Colony-Stimulating Factor has been clinically used for twenty years since it was on the market in 1999, the export volume has exceeded all competitive products in domestic market. Strict internal control quality standards has made Recombinant Human Granulocyte Colony-Stimulating Factor meet quality requirements of both Chinese Pharmacopoeia and European Pharmacopoeia.
In 2002, White-C won China's high-quality product certificate issued by the Association Technologie Nouvelle de France and was classified as recommended product for the EU market by the China Council for the Promotion of International Trade Department of Media Press and the Association technologie Nouvelle de France.
National patent production varieties, winner of golden prize for liver disease.
The original recipe of Kehuang Capsule is from Quanzhou, Fujian. It is a precious medicine which is derived from Musk, Bezoar, Borneol, Sambo, Panax and etc. The treatment effect has been found as early as 1927 when jaundice disease happened. In 1989, the drug played its role in "reduced jaundice and reduced enzyme" when the hepatitis A swept Shanghai. In the same year, Shenzhen Tongan bought the secret ingredients and invested a huge amount of money for development. After six years of passing strict provisions for state-level approval for new drugs. With nearly 100 national and provincial experts’ participated in the project, the product reached the quality standards, and toxicology and clinical research have been conducted. In 1994, the product have been granted as national new drug certificate and approved for producing.
As a Chinese medicine with an exclusive formula for reduced jaundice and reduced enzyme, Kehuang Capsule is the first batch of protected variety of state secrets traditional Chinese medicine. It was identified as state-level new products by the State Science and Technology Commission and other five ministries, and was included in the National Spark Program.
First Class New Drug in National New Drug Development Fund Plan
Combined Clostridium Butyricum and Bifidobacterium Powder/Capsule with the patent, the only probiotics approved by CFDA for young and old, and pregnant people. It is a most widely clinical application, and supported by microecological preparations.
Global brand endorsement, probiotic solid drinks
Genzon Pharmaceutical first introced a health care products from abroad, Bio-Efficacité probiotic solid drinks, which is produced by lallemand SAS, the global pioneer of global probiotic research and application. It has two probiotics research center and five factories with GMP license. With the global brand background, the good reputation has been secured in terms of quality.